title: An exploratory analysis of factors associated with weight change in a 16-week trial of oral vs. orally disintegrating olanzapine: the PLATYPUS study.
abstract: BACKGROUND
  We conducted exploratory analyses of the data from a multinational, randomised study to identify factors associated with weight change after 16 weeks of treatment with standard olanzapine tablets (SOT) or sublingual orally disintegrating olanzapine (ODO).
  
  
  METHODS
  One hundred and forty nine outpatients who gained weight during prior SOT therapy were enrolled into the study and treated with ODO (N = 84) or SOT (N = 65). Exploratory analyses were conducted with the subset of compliant patients (ODO: n = 60; SOT: n = 47).
  
  
  RESULTS
  The decrease in the rate of weight gain at the end of study therapy (change from baseline) was greater in the ODO group than the SOT group (-0.59 kg/week vs. -0.38 kg/week, p = 0.0246). Age was negatively associated with weight change (p = 0.0203) in both treatment groups combined: patients gained 0.7 kg less for every 10 years of age. The least squares mean weight gain was lower with ODO than SOT in male patients (0.35 kg vs. 3.04 kg, p = 0.061), but not female patients and in American patients (0.55 kg vs. 6.21 kg, p < 0.0001), but not Canadian or Mexican patients.
  
  
  CONCLUSIONS
  Although not conclusive, these data suggest that ODO may be a reasonable treatment option for some patients who gain weight with SOT. Further research is required to confirm these findings.
authors.affiliation: Eli Lilly Canada Inc., Toronto, ON, CanadaFaculty of Medicine, Discipline of Psychiatry, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, CanadaEli Lilly and Company, Indianapolis, IN, USADepartment of Medicine, Faculty of Medicine, University of Toronto and St. Michael's Hospital, Toronto, ON, CanadaDepartment of Psychiatry, Academic Medical Center, University of Amsterdam, Amsterdam, The NetherlandsDepartment of Psychiatry, University of California, Irvine, CA, USADepartment of Psychiatry, Queen's University, Kingston, ON, CanadaIntercontinental Information Sciences, Eli Lilly Australia Pty. Limited, Macquarie Park, NSW, Australia.
authors.forename: J
authors.initials: J
authors.lastname: Karagianis
authors.affiliation: Eli Lilly Canada Inc., Toronto, ON, CanadaFaculty of Medicine, Discipline of Psychiatry, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, CanadaEli Lilly and Company, Indianapolis, IN, USADepartment of Medicine, Faculty of Medicine, University of Toronto and St. Michael's Hospital, Toronto, ON, CanadaDepartment of Psychiatry, Academic Medical Center, University of Amsterdam, Amsterdam, The NetherlandsDepartment of Psychiatry, University of California, Irvine, CA, USADepartment of Psychiatry, Queen's University, Kingston, ON, CanadaIntercontinental Information Sciences, Eli Lilly Australia Pty. Limited, Macquarie Park, NSW, Australia.
authors.forename: J
authors.initials: J
authors.lastname: Landry
authors.affiliation: Eli Lilly Canada Inc., Toronto, ON, CanadaFaculty of Medicine, Discipline of Psychiatry, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, CanadaEli Lilly and Company, Indianapolis, IN, USADepartment of Medicine, Faculty of Medicine, University of Toronto and St. Michael's Hospital, Toronto, ON, CanadaDepartment of Psychiatry, Academic Medical Center, University of Amsterdam, Amsterdam, The NetherlandsDepartment of Psychiatry, University of California, Irvine, CA, USADepartment of Psychiatry, Queen's University, Kingston, ON, CanadaIntercontinental Information Sciences, Eli Lilly Australia Pty. Limited, Macquarie Park, NSW, Australia.
authors.forename: V P
authors.initials: VP
authors.lastname: Hoffmann
authors.affiliation: Eli Lilly Canada Inc., Toronto, ON, CanadaFaculty of Medicine, Discipline of Psychiatry, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, CanadaEli Lilly and Company, Indianapolis, IN, USADepartment of Medicine, Faculty of Medicine, University of Toronto and St. Michael's Hospital, Toronto, ON, CanadaDepartment of Psychiatry, Academic Medical Center, University of Amsterdam, Amsterdam, The NetherlandsDepartment of Psychiatry, University of California, Irvine, CA, USADepartment of Psychiatry, Queen's University, Kingston, ON, CanadaIntercontinental Information Sciences, Eli Lilly Australia Pty. Limited, Macquarie Park, NSW, Australia.
authors.forename: L
authors.initials: L
authors.lastname: Grossman
authors.affiliation: Eli Lilly Canada Inc., Toronto, ON, CanadaFaculty of Medicine, Discipline of Psychiatry, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, CanadaEli Lilly and Company, Indianapolis, IN, USADepartment of Medicine, Faculty of Medicine, University of Toronto and St. Michael's Hospital, Toronto, ON, CanadaDepartment of Psychiatry, Academic Medical Center, University of Amsterdam, Amsterdam, The NetherlandsDepartment of Psychiatry, University of California, Irvine, CA, USADepartment of Psychiatry, Queen's University, Kingston, ON, CanadaIntercontinental Information Sciences, Eli Lilly Australia Pty. Limited, Macquarie Park, NSW, Australia.
authors.forename: L
authors.initials: L
authors.lastname: De Haan
authors.affiliation: Eli Lilly Canada Inc., Toronto, ON, CanadaFaculty of Medicine, Discipline of Psychiatry, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, CanadaEli Lilly and Company, Indianapolis, IN, USADepartment of Medicine, Faculty of Medicine, University of Toronto and St. Michael's Hospital, Toronto, ON, CanadaDepartment of Psychiatry, Academic Medical Center, University of Amsterdam, Amsterdam, The NetherlandsDepartment of Psychiatry, University of California, Irvine, CA, USADepartment of Psychiatry, Queen's University, Kingston, ON, CanadaIntercontinental Information Sciences, Eli Lilly Australia Pty. Limited, Macquarie Park, NSW, Australia.
authors.forename: G
authors.initials: G
authors.lastname: Maguire
authors.affiliation: Eli Lilly Canada Inc., Toronto, ON, CanadaFaculty of Medicine, Discipline of Psychiatry, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, CanadaEli Lilly and Company, Indianapolis, IN, USADepartment of Medicine, Faculty of Medicine, University of Toronto and St. Michael's Hospital, Toronto, ON, CanadaDepartment of Psychiatry, Academic Medical Center, University of Amsterdam, Amsterdam, The NetherlandsDepartment of Psychiatry, University of California, Irvine, CA, USADepartment of Psychiatry, Queen's University, Kingston, ON, CanadaIntercontinental Information Sciences, Eli Lilly Australia Pty. Limited, Macquarie Park, NSW, Australia.
authors.forename: R
authors.initials: R
authors.lastname: Milev
authors.affiliation: Eli Lilly Canada Inc., Toronto, ON, CanadaFaculty of Medicine, Discipline of Psychiatry, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, CanadaEli Lilly and Company, Indianapolis, IN, USADepartment of Medicine, Faculty of Medicine, University of Toronto and St. Michael's Hospital, Toronto, ON, CanadaDepartment of Psychiatry, Academic Medical Center, University of Amsterdam, Amsterdam, The NetherlandsDepartment of Psychiatry, University of California, Irvine, CA, USADepartment of Psychiatry, Queen's University, Kingston, ON, CanadaIntercontinental Information Sciences, Eli Lilly Australia Pty. Limited, Macquarie Park, NSW, Australia.
authors.forename: S
authors.initials: S
authors.lastname: Holt
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D014150:Antipsychotic Agents / Q000008:administration & dosage*; D001569:Benzodiazepines / Q000008:administration & dosage*; D001714:Bipolar Disorder / Q000188:drug therapy*; D015992:Body Mass Index; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077152:Olanzapine; D011618:Psychotic Disorders / Q000188:drug therapy*; D017678:Sex Distribution; D013607:Tablets; D015430:Weight Gain / Q000187:drug effects*; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D013607:Tablets; D001569:Benzodiazepines; D000077152:Olanzapine